Help us: Donate
Follow us on:
×

Tag: UNITY Biotechnology

August 18, 2020
While we enjoy reporting positive news, we do occasionally have to report bad news, and today is one of those days. There has been some disappointing news from UNITY Biotechnology with the release of its Phase 2 senolytic trial of its candidate drug UBX0101. SOUTH SAN FRANCISCO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- UNITY...
July 14, 2020
In this premier episode of Lifespan News, Brent Nally discusses Unity Biotechnology's human trials of novel senolytic drugs, including a Phase 2 human trial of a senolytic drug for knee osteoarthritis; two proteins that allow LDL cholesterol to enter our cells; Ponce de Leon Health and epigenetic age reversal; the reason why naked mole rats...
June 05, 2020
Don’t let your birthday get you down and remind you that you are getting older; there are plenty of reasons to be cheerful about the future and your place in it, especially as science is now turning its attention to aging. Another trip around the sun So here I am again, another birthday just gone...
January 24, 2020
The Longevity Therapeutics conference enters its second year, opening its doors on January 28th for a three-day event focused on aging research. If you are interested in the actual science happening in the field with no snake oil in sight, then this is the West Coast conference to attend. With over 80 speakers, including researchers,...
June 19, 2019
Recently, Unity Biotechnology completed a phase 1 trial of its drug UBX0101. While the trial found that the drug was non-toxic and lacked serious side effects, many of its results were not statistically significant. UBX0101 UBX0101 aims to treat osteoarthritis and possibly other diseases of aging through directly targeting one of the aspects of aging...
March 22, 2019
On July 11-12th, we return to the Cooper Union in New York City for our second annual Ending Age-Related Diseases conference, which focuses on the progress in aging research as well as the business side of biotech. We will be bringing you the latest aging research, investment, and business knowledge from some of the top...